{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"100","value":"38.9"},{"groupId":"OG001","spread":"102","value":"27.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"179"}],"units":"Participants"}],"title":"Cycle 1 Day 15/ predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"57.7","value":"41.3"},{"groupId":"OG001","spread":"88.6","value":"28.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"168"}],"units":"Participants"}],"title":"Cycle 1 Day 15/ 3-6 hr"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"105","value":"39.2"},{"groupId":"OG001","spread":"202","value":"24.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"168"},{"groupId":"OG001","value":"158"}],"units":"Participants"}],"title":"Cycle 4 Day 15/ predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"59.4","value":"42.3"},{"groupId":"OG001","spread":"135","value":"26.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"168"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"title":"Cycle 4 Day 15/ 3-6 hr postdose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"209"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received vemurafenib, 960 mg (four, 240 mg tablets), PO, BID along with cobimetinib, 60 mg (three, 20 mg tablets) PO, QD on Days 1 to 21 only followed by vemurafenib 960 mg (four, 240 mg tablets), PO, BID on Days 22 to 28 during the 28 day run-in period. During triple combination period (Cycle 1 onwards), participants received atezolizumab matching placebo as IV infusion on Days 1 and 15, cobimetinib, 60 mg (three, 20 mg tablets) PO, QD, on Days 1 to 21 and vemurafenib 960 mg (four, 240 mg tablets) PO, BID on Days 1 to 28. Study treatment was continued until investigator determined PD, death, unacceptable toxicity, withdrawal of consent, or pregnancy, whichever occurred first.","id":"OG000","title":"Arm A: Pbo + Cobi + Vem"},{"description":"Participants received vemurafenib, 960 mg (four, 240 mg tablets) PO, BID along with cobimetinib 60 mg (three, 20 mg tablets) PO, QD on Days 1 to 21 only followed by vemurafenib 720 mg (three, 240 mg tablets) PO, BID and vemurafenib matching placebo, PO, BID on Days 22 to 28 during the 28 day run-in period. During triple combination period (Cycle 1 onwards), participants received atezolizumab 840 mg as IV infusion on Days 1 and 15, cobimetinib, 60 mg (three, 20 mg tablets) PO, QD, on Days 1 to 21, vemurafenib 720 mg (three, 240 mg tablets) PO BID on Days 1 to 28, and vemurafenib placebo (1 tablet) PO BID on Days 1 to 28. Study treatment was continued until investigator determined PD, death, unacceptable toxicity, withdrawal of consent, or pregnancy, whichever occurred first.","id":"OG001","title":"Arm B: Atezo + Cobi + Vem"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The Vem PK-evaluable population included all participants who received any dose of vemurafenib and for whom at least one evaluable PK sample was collected. Number analyzed is the number of participants with data available for analysis at the specified timepoint.","reportingStatus":"POSTED","timeFrame":"Pre-dose (0 hour) and 3 to 6 hours post dose on Day 15 of Cycles 1 and 4 (1 Cycle = 28 days)","title":"Plasma Concentration of Vemurafenib","type":"SECONDARY","unitOfMeasure":"μg/mL"}